DepoMed, Inc. (NASDAQ:DEPO)
CAPS Rating:
A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.
RSS Headlines
Fool UK
Recs
Gralise should be able to compete with generics. ER tech should pay dividends down the road.